Literature DB >> 29896031

Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia.

Stepan Uhlyar, Jose A Rey.   

Abstract

Valbenazine (Ingrezza): the first FDA-approved treatment for tardive dyskinesia.

Entities:  

Year:  2018        PMID： 29896031      PMCID： PMC5969209     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  13 in total

1.  Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.

Authors:  Dimitri E Grigoriadis; Evan Smith; Sam R J Hoare; Ajay Madan; Haig Bozigian
Journal:  J Pharmacol Exp Ther       Date:  2017-04-12       Impact factor: 4.030

2.  Health insurance coverage among persons with schizophrenia in the United States.

Authors:  Elizabeth Khaykin; William W Eaton; Daniel E Ford; Christopher B Anthony; Gail L Daumit
Journal:  Psychiatr Serv       Date:  2010-08       Impact factor: 3.084

Review 3.  Tetrabenazine for the treatment of tardive dyskinesia.

Authors:  Jonathan G Leung; Ericka L Breden
Journal:  Ann Pharmacother       Date:  2011-04-12       Impact factor: 3.154

4.  KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.

Authors:  Robert A Hauser; Stewart A Factor; Stephen R Marder; Mary Ann Knesevich; Paul M Ramirez; Roland Jimenez; Joshua Burke; Grace S Liang; Christopher F O'Brien
Journal:  Am J Psychiatry       Date:  2017-03-21       Impact factor: 18.112

5.  Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.

Authors:  Scott W Woods; Hal Morgenstern; John R Saksa; Barbara C Walsh; Michelle C Sullivan; Roy Money; Keith A Hawkins; Ralitza V Gueorguieva; William M Glazer
Journal:  J Clin Psychiatry       Date:  2010-02-09       Impact factor: 4.384

6.  Valbenazine granted breakthrough drug status for treating tardive dyskinesia.

Authors:  Thomas Müller
Journal:  Expert Opin Investig Drugs       Date:  2015-03-25       Impact factor: 6.206

Review 7.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

8.  Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale.

Authors:  R D Lane; W M Glazer; T E Hansen; W H Berman; S I Kramer
Journal:  J Nerv Ment Dis       Date:  1985-06       Impact factor: 2.254

Review 9.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

10.  NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.

Authors:  Christopher F O'Brien; Roland Jimenez; Robert A Hauser; Stewart A Factor; Joshua Burke; Daniel Mandri; Julio C Castro-Gayol
Journal:  Mov Disord       Date:  2015-09-08       Impact factor: 10.338
View more
  2 in total

Review 1.  Valbenazine for the Treatment of Adults with Tardive Dyskinesia.

Authors:  Harshit Gupta; Alycee R Moity; Allison Jumonville; Sarah Kaufman; Amber N Edinoff; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-18

Review 2.  Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy.

Authors:  Anamaria Jurcau; Maria Carolina Jurcau
Journal:  Biomedicines       Date:  2022-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.